Search Results - "Heal, J"

Refine Results
  1. 1

    Amphetamine, past and present – a pharmacological and clinical perspective by Heal, David J, Smith, Sharon L, Gosden, Jane, Nutt, David J

    Published in Journal of psychopharmacology (Oxford) (01-06-2013)
    “…Amphetamine was discovered over 100 years ago. Since then, it has transformed from a drug that was freely available without prescription as a panacea for a…”
    Get full text
    Journal Article
  2. 2

    A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids by Heal, David J, Gosden, Jane, Smith, Sharon L

    Published in Frontiers in psychiatry (10-06-2024)
    “…Various countries and US States have legalized cannabis, and the use of the psychoactive and non-psychoactive cannabinoids is steadily increasing. In this…”
    Get full text
    Journal Article
  3. 3

    Hypoalbuminaemia and its association with disease and clinical outcomes in cats by Fong, K. Y. M., Oikonomidis, I. L., Leong, D., Lo, G., Heal, J., Woods, G.

    Published in Journal of small animal practice (01-10-2024)
    “…Objectives To report the incidence of feline hypoalbuminaemia and characterise the distribution of presenting disease categories and pathoaetiologies of…”
    Get full text
    Journal Article
  4. 4

    Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence by Gray, Royston A, Heal, David J, Maguire, David R, Gerak, Lisa R, Javors, Martin A, Smith, Sharon, France, Charles P

    “…Cannabidiol (CBD) is a constituent of the cannabis plant with a diverse array of pharmacological activities as well as potential therapeutic uses. An oral…”
    Get full text
    Journal Article
  5. 5

    Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans by Heal, David J., Gosden, Jane, Smith, Sharon L.

    Published in Neuropharmacology (01-11-2018)
    “…Psychedelics comprise drugs come from various pharmacological classes including 5-HT2A agonists, indirect 5-HT agonists, e.g., MDMA, NMDA antagonists and…”
    Get full text
    Journal Article
  6. 6

    Evolutionary Developments in Interpreting the  Gluten-Induced Mucosal Celiac Lesion: An  Archimedian Heuristic by Marsh, Michael N, Heal, Calvin J

    Published in Nutrients (28-02-2017)
    “…The evolving history of the small intestinal biopsy and its interpretation-and misinterpretations-are described in this paper. Certain interpretative errors in…”
    Get full text
    Journal Article
  7. 7

    A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil by Heal, David J., Buckley, Niki W., Gosden, Jane, Slater, Nigel, France, Charles P., Hackett, David

    Published in Neuropharmacology (01-10-2013)
    “…Lisdexamfetamine dimesylate, which consists of l-lysine covalently bound to d-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to…”
    Get full text
    Journal Article
  8. 8

    ABO-immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non-identical transfusion by Zaffuto, B. J., Conley, G. W., Connolly, G. C., Henrichs, K. F., Francis, C. W., Heal, J. M., Blumberg, N., Refaai, M. A.

    Published in Vox sanguinis (01-04-2016)
    “…Background Transfusion of ABO non‐identical platelets has been associated with fatal haemolytic reactions, increased red cell transfusion needs and other…”
    Get full text
    Journal Article
  9. 9

    Inhibition of HIV-1 protease: the rigidity perspective by Heal, J. W., Jimenez-Roldan, J. E., Wells, S. A., Freedman, R. B., Römer, R. A.

    Published in Bioinformatics (01-02-2012)
    “…Motivation: HIV-1 protease is a key drug target due to its role in the life cycle of the HIV-1 virus. Rigidity analysis using the software First is a…”
    Get full text
    Journal Article
  10. 10

    Pharmacological Differences Between Rat Frontal Cortex and Hippocampus in the Nicotinic Modulation of Noradrenaline Release Implicate Distinct Receptor Subtypes by Kennett, Alexandra, Heal, David J., Wonnacott, Susan

    Published in Nicotine & tobacco research (01-11-2012)
    “…Noradrenergic mechanisms in frontal cortex and hippocampus are relevant to attentional and stress-related aspects of addiction, respectively. Nicotinic…”
    Get full text
    Journal Article
  11. 11

    A review of late-stage CNS drug candidates for the treatment of obesity by Heal, D J, Gosden, J, Smith, S L

    Published in International Journal of Obesity (01-01-2013)
    “…Obesity is an important causative factor in morbidity, disability and premature death. Increasing levels of obesity will impose enormous health, financial and…”
    Get full text
    Journal Article
  12. 12

    The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety by Heal, D.J., Cheetham, S.C., Smith, S.L.

    Published in Neuropharmacology (01-12-2009)
    “…Results from in vivo techniques, especially intracerebral microdialysis in freely-moving rats, have provided insights into potential mechanisms responsible for…”
    Get full text
    Journal Article
  13. 13

    Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine‐conditioned place preference and associated changes in AMPA receptor binding by Wright, Victoria L., Georgiou, Polymnia, Bailey, Alexis, Heal, David J., Bailey, Christopher P., Wonnacott, Susan

    Published in Addiction biology (01-07-2019)
    “…Recurrent relapse is a major problem in treating opiate addiction. Pavlovian conditioning plays a role in recurrent relapse whereby exposure to cues learned…”
    Get full text
    Journal Article
  14. 14

    What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials by Heal, David J., Gosden, Jane

    Published in International Journal of Obesity (01-04-2022)
    “…Binge-eating disorder (BED) is the commonest eating disorder and an important causal factor in obesity. Lisdexamfetamine is the only approved pharmacological…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology by Heal, David J, Smith, Sharon L

    Published in Journal of Psychopharmacology (01-06-2022)
    “…Background: Binge-eating disorder (BED) is a common psychiatric condition with adverse psychological and metabolic consequences. Lisdexamfetamine (LDX) is the…”
    Get full text
    Book Review Journal Article
  17. 17

    Thermogenic effects of sibutramine and its metabolites by Connoley, Ian P, Liu, Yong‐Ling, Frost, Ian, Reckless, Ian P, Heal, David J, Stock, Michael J

    Published in British journal of pharmacology (01-03-1999)
    “…The thermogenic activity of the serotonin and noradrenaline reuptake inhibitor sibutramine (BTS 54524; Reductil) was investigated by measuring oxygen…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder by Heal, David J, Gosden, Jane, Smith, Sharon L

    Published in Advances in pharmacology (1990) (2024)
    “…In this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder…”
    Get more information
    Journal Article